AMD

Age-related Macular Degeneration

Cause

Digital Device and Blue Ray (Blue Light : HEV)
Danger for the Retina

  • What is the current blockbuster drug for AMD?

    • Wet AMD blockbuster drugs: Lucentis, Eylea, Vabysmo (longer dosing intervals).

    • Dry AMD : N/A

    • New therapies in trials include gene therapies and small molecules targeting early disease mechanisms.

  • What is the prevalence of wet and dry AMD?

    • Dry AMD is the more common form overall, representing about 85-90% of AMD cases, including early and intermediate stages.

    • Wet AMD accounts for approximately 10-15% of AMD cases but is responsible for the majority of severe vision loss.

  • Eylea (aflibercept), Lucentis (ranibizumab), and the newer Vabysmo (faricimab) are treatments for wet AMD.

    What about your treatment?

    • Our drug is designed to treat both wet and dry AMD, addressing a broader spectrum of the disease compared to current anti-VEGF therapies like Eylea, Lucentis, and Vabysmo, which are primarily for wet AMD. This dual coverage represents an advancement in treating both forms of AMD.

AMD Cure by Regeneration

  • Validation of the Efficacy of Age-related Macular Degeneration (AMD) Prevention and Regeneration of the Outer Nuclear Layer (ONL) and Inner Nuclear Layer (INL), as well as Suppression of Glial Fibrillary Acidic Protein (GFAP) Expression in the Ganglion Cell Layer (GCL), signifying a groundbreaking leap in first-in-class redox drug development.

  • The b-wave values in the ERG for AOAN0104 demonstrate approximately three times greater regeneration, implying a potential curative effect rather than mere amelioration or slowing down of the progression observed with current treatment options such as aflibercept (Eylea®).

Subscribe

Subscribe